Kenneth Carl Anderson, M.D.
This page shows the publications co-authored by Kenneth Anderson and Elizabeth O'Donnell.
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 Feb 15.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212.
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161.
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 Apr; 36(4):1078-1087.
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.